Viking Therapeutics 3Q 2026: Revenue $0 Net loss $183.2M, EPS $(1.55) — 10-Q Summary
Viking Therapeutics reported no revenue and a net loss of $183.2M for 3Q 2026, up 101.8% YoY. Diluted loss per share was $1.55. The company completed enrollment for VANQUISH-1 and VANQUISH-2 trials for VK2735 and began the SUNRISE Phase 3 program, showing weight reductions up to 12.2%.
How this was made
The 30-second read
Why it matters
The earnings miss and lack of revenue increase pressure the stock, while trial progress may offer future upside.
Market read
Primary earnings disclosure for a US‑listed biotech; relevant for traders monitoring sector risk and pipeline milestones.
What to watch
Positive Phase 3 data could attract speculative interest despite the earnings miss.
Background
Viking Therapeutics (VKTX) filed its Q3 2026 10‑Q, reporting zero revenue, a widened net loss, and updates on multiple clinical programs.
Ticker impact
Viking Therapeutics disclosed Q3 2026 results with $183.2M net loss and Phase 3 trial enrollment updates.
likely downward pressure as investors price in the larger loss and uncertain trial outcomes
The company reported a 101% YoY increase in net loss and no revenue, which typically triggers sell‑offs in biotech micro‑caps.
Market effects
Biotech sector may see broader risk‑off sentiment as a peer reports a sizable loss.
US biotech investors likely react; limited impact outside the sector.
Minimal global effect beyond biotech-focused funds.
Counterpoint
If Phase 3 enrollment signals strong pipeline potential, the loss may be viewed as a short‑term pain for long‑term upside.
Key entities
- companyViking Therapeutics
Biotech firm developing obesity and liver disease therapies.
